Market closedADR
GSK/$GSK
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About GSK
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Ticker
$GSK
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
70,212
Website
GSK Metrics
BasicAdvanced
$68B
Market cap
43.97
P/E ratio
$0.76
EPS
0.33
Beta
$1.51
Dividend rate
4.54%
Dividend yield
Price and volume
Market cap
$68B
Beta
0.33
52-week high
$45.93
52-week low
$32.83
Average daily volume
5.6M
Dividend rate
$1.51
Financial strength
Current ratio
0.806
Quick ratio
0.516
Long term debt to equity
98.446
Total debt to equity
119.371
Dividend payout ratio (TTM)
95.58%
Interest coverage (TTM)
10.83%
Management effectiveness
Return on assets (TTM)
7.24%
Return on equity (TTM)
21.85%
Valuation
Price to earnings (TTM)
43.972
Price to revenue (TTM)
3.476
Price to book
3.84
Price to tangible book (TTM)
-7.01
Price to free cash flow (TTM)
22.134
Dividend yield (TTM)
4.49%
Forward dividend yield
4.54%
Growth
Revenue change (TTM)
5.59%
Earnings per share change (TTM)
-58.92%
3-year revenue growth (CAGR)
5.91%
3-year earnings per share growth (CAGR)
-17.09%
3-year dividend per share growth (CAGR)
-15.19%
What the Analysts think about GSK
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for GSK stock.
GSK Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
GSK Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
GSK News
AllArticlesVideos
GSK's FIRST trial achieves progression-free survival milestone in advanced ovarian cancer
Proactive Investors·4 days ago
GSK's cancer drugs meet progression-free survival goal in late-stage trial
Reuters·4 days ago
GSK passes three significant milestones with new cancer drug given a double boost
Proactive Investors·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Market closedADR
Upcoming events
Jan
9
GSK
Dividend·Payment
$0.389052
Per share
FAQs
What’s the current market cap for GSK stock?
GSK (GSK) has a market cap of $68B as of December 24, 2024.
What is the P/E ratio for GSK stock?
The price to earnings (P/E) ratio for GSK (GSK) stock is 43.97 as of December 24, 2024.
Does GSK stock pay dividends?
Yes, the GSK (GSK) stock pays dividends to shareholders. As of December 24, 2024, the dividend rate is $1.50835 and the yield is 4.54%. GSK has a payout ratio of 95.58% on a trailing twelve-month basis.
When is the next GSK dividend payment date?
The next GSK (GSK) dividend payment is scheduled for January 09, 2025.
What is the beta indicator for GSK?
GSK (GSK) has a beta rating of 0.33. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.